Plus, get the best of BroadwayWorld delivered to your inbox, and unlimited access to our editorial content across the globe. The University of Arizona's School of Theatre, Film & Television (TFTV) ...
Please provide your email address to receive an email when new articles are posted on . Tisotumab vedotin-tftv prolonged OS compared with chemotherapy alone among women with recurrent or metastatic ...
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics ...
3 ICYMI: Next On Stage: Season 5- Meet the Top 5 4 ICYMI: Meet the Next On Stage: Season 6 Finalists Caryl Churchill's intriguing mosaic offers no through-line to latch onto, only fragments that ...
Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK&circledR ...
COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic ...
TIVDAK (tisotumab vedotin-tftv) is an ADC composed of Genmab’s human monoclonal antibody directed to tissue factor (TF) and Seagen’s ADC technology that utilizes a protease-cleavable linker that ...
-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan-- -- Zai Lab will ...
Submission based on positive results from global phase 3 innovaTV 301 trial demonstrating overall survival benefit of tisotumab vedotin-tftv over chemotherapy The sBLA is supported by efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results